Nivolumab induced myxedema crisis
ConclusionNivolumab can cause immune-mediated endocrinopathies including thyroiditis, hypophysitis, adrenal insufficiency and type 1 diabetes mellitus. High index of suspicion and periodic measurement of thyroid function tests are recommended in patients receiving nivolumab therapy. Our case also suggests that once the myxedema crisis is treated and symptoms are resolved, nivolumab can be safely re-challenged.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
More News: Addison's Disease | Adrenal Insufficiency | Cancer | Cancer & Oncology | Carcinoma | Depression | Diabetes | Diabetes Mellitus | Diabetes Type 1 | Endocrinology | Hormones | Hypothyroidism | Immunotherapy | Kidney Cancer | Levothyroxine | Lung Cancer | Lymphoma | Melanoma | Men | Non-Small Cell Lung Cancer | Renal Cell Carcinoma | Skin Cancer | Squamous Cell Carcinoma | Synthroid | Thyroid | Thyroid Cancer | Thyroiditis